Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis

Table 5 Bivariate analysis with Cox proportional hazard model

		Local recurrence			Recurrence-free survival
Variable		Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Nottigham grade	2 vs. 3	0.30	0.05–1.81	0.43	0.67	0.24–1.88	0.75
Menopausal status	Post vs. pre	0.25	0.03–2.10	0.44	1.32	0.57–3.06	0.81
LVI	No vs. Yes	0.69	0.15–3.08	0.63	0.48	0.19–1.22	0.12
Pathological nodal status	No vs. yes	1.33	0.16–11.03	0.79	0.41	0.05–3.05	0.38
Tumour size before surgery		1.09	0.86–1.38	0.47	1.24	1.08–1.42	0.003
Tumour size at surgery		1.03	0.85–1.24	0.77	1.18	1.09–1.29	< 0.001
Miller-Payne score		0.74	0.42–1.32	0.31	0.56	0.4–0.8	0.001
Chevallier score		0.96	0.46–2.02	0.92	2.01	1.14–3.53	0.015
Standard pathology response				0.51			0.05
	NR vs. pCR	3.98	0.36–44.0		13.29	1.6–110.5
	PR vs. pCR	2.07	0.24–17.7		7.43	0.99–56.1
Pretreatment stage group				0.51			0.05
	II vs. III	0.62	0.15–2.61		0.41	0.17–1.0

Abbreviations: CI confidence interval, LVI lymphovascular invasion, NR no response, pCR pathological complete response, PR partial response